Lung neoplasm; Iressa; Toxicity reaction; Treatment outcome.
肺腺癌；易瑞沙；毒副反应；治疗结果。
Doctor, the profile that you just read is actually for (gefitinib) IRESSA.
医生，刚才您所阅读的简介其实就是(吉非替尼)易瑞沙。
The recommended daily dose of IRESSA is one 250 mg tablet with or without food.
建议的每日剂量易瑞沙是250毫克片剂或无食物。
How would you use IRESSA? For which lines of therapy and for which patients? Why?
您会如何使用易瑞沙？会用于几线治疗？用于哪些患者？为什么？
I would like you to imagine that you are presenting information about IRESSA to your peers.
现在假设您需要向您的同事阐述关于易瑞沙的一些信息。
Would you consider using IRESSA in patients who otherwise be suitable for chemotherapy? Why?
对于适用化疗的患者您是否会考虑使用易瑞沙？为什么？
Based on what you read, how likely would you be to use IRESSA as 1st line treatment in advanced NSCLC in your patients?
根据您刚才读的内容，您对于晚期NSCLC患者使用易瑞沙作为一线治疗的意愿有多大？
Iressa from AstraZeneca and Vectibix from Amgen are among EGFR blockers now available to treat colorectal, lung, breast and other cancers.
阿斯利康公司的Iressa和Amgen公司的Vectibix是目前用于临床治疗结直肠肿瘤、肺癌、乳腺癌和其他肿瘤的EGFR拮抗剂。
Now knowing that this product is referring to IRESSA, how do you feel? Does this information change your perception of the product? Why and how so?
现在知道这个产品就是易瑞沙，您有什么感觉？这些信息是否影响了您对该产品的认知？为什么？怎样影响？
I would now like to focus for the remainder of our discussion on how best to convey a compelling picture for Iressa in advanced NSCLC as 1st line in EGFR mutation positive patients.
在此次访问的最后部分我想请各位阐述以下如何才能最好的传达一幅引人注目的画面，说明易瑞沙是针对EGFR突变阳性的晚期NSCLC患者的一线治疗方法。
I would now like to focus for the remainder of our discussion on how best to convey a compelling picture for Iressa in advanced NSCLC as 1st line in EGFR mutation positive patients.
在此次访问的最后部分我想请各位阐述以下如何才能最好的传达一幅引人注目的画面，说明易瑞沙是针对EGFR突变阳性的晚期NSCLC患者的一线治疗方法。
应用推荐